Results 131 to 140 of about 126,252 (309)

Review for "A Twelve‐Week, Randomized, Double‐Blind, Placebo‐Controlled, Four‐Arm Dose‐Finding Phase 2 Study Evaluating Bexagliflozin as a Monotherapy for Adults with Type 2 Diabetes"

, 2019

openalex   +1 more source

Editorial: Optimizing the therapeutic potential in clinical settings: leveraging placebos and mitigating nocebo effects. [PDF]

Front Psychol
Faria V, Bernstein M, Annoni M, Furmark T, Moulton EA.   +4 more
europepmc   +1 more source

Computer Library Literature Review on Effectiveness of Antimotion Sickness Drugs [PDF]

Physiological responses to antimotion sickness drugs - antihistamines, belladonnas, and ...
Graybiel, A., Kennedy, R. S., Trumbull, R., Wherry, R. J., Jr., Wood, C. D.   +4 more
core   +1 more source

Anifrolumab Treatment Leads to Rapid Reduction in Urinary Biomarkers of Intrarenal Inflammation in Lupus Nephritis: Results From the Phase 2 Randomized Trial

Arthritis &Rheumatology, EarlyView.
Objective Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE) and is partially driven by type I interferon signaling. Anifrolumab, an approved treatment for patients with SLE, has been investigated in a phase 2 trial in patients with LN receiving standard therapy (TULIP‐LN, ClinicalTrials.gov identifier ...
Andrea Fava, Michelle Petri, Patrick G. Gavin, Eszter Csomor, Philip Z. Brohawn, Daniel Muthas, Adam Platt, Catharina Lindholm, Nicola Ferrari   +8 more
wiley   +1 more source

Placebo Discontinuity Design [PDF]

Rahul Kumar Singh, Stewart, Moses
openalex   +1 more source

Ethical challenges of placebo use in herbal medicine trials: multiple stakeholder perspectives from qualitative interviews. [PDF]

BMC Med Ethics
Li Y, Zhang X, Qi B, Gao J, Pang X, Zhang C.   +5 more
europepmc   +1 more source

Treatment of a Large Cohort of Childhood Chronic Noninfectious Uveitis in a Multicentric Large Study: Adalimumab Versus Methotrexate as First‐Line Therapy

Arthritis &Rheumatology, EarlyView.
Objective Treatment of childhood chronic idiopathic uveitis (cCIU) is predominantly based on studies in juvenile idiopathic arthritis–associated uveitis and expert opinion. Our aim was to report the treatment outcomes of our cohort of cCIU. Methods Retrospective multicenter study involving the rheumatology and ophthalmology units at Florence, Italy ...
Ilaria Maccora, Catherine Guly, Cinzia de Libero, Giulia Carreras, Athimalaipet V. Ramanan, Gabriele Simonini   +5 more
wiley   +1 more source

Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell lymphoma receiving R-CHOP [PDF]

R Nemec, Marielle Scherrer‐Crosbie, Jeremy S. Abramson, Robert Redd, Hannah Gilman, Terry Ho, Jessica Wu, Julius C. Heemelaar, Donna Neuberg, Ephraim P. Hochberg, Jeffrey A. Barnes, Philippe Armand, Eric D. Jacobsen, Caron A. Jacobson, Austin I. Kim, Robb S. Friedman, Ann S. LaCasce, Tomas G. Neilan, Jacob D. Soumerai   +18 more
openalex   +1 more source

TACE with Lenvatinib and Pembrolizumab in Unresectable, Nonmetastatic Hepatocellular Carcinoma: Results from the LEAP-012 Trial. [PDF]

Radiol Imaging Cancer
Siddiqi NS.
europepmc   +1 more source

Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of a Phase 3, Randomized, Placebo‐Controlled Study

Arthritis &Rheumatology, EarlyView.
Objective To evaluate the efficacy and safety of guselkumab, an interleukin‐23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor (TNF) inhibitor.
Alexis Ogdie, Joseph F. Merola, Philip J. Mease, Christopher T. Ritchlin, Jose U. Scher, Kimberly Parnell Lafferty, Daphne Chan, Soumya D. Chakravarty, Wayne Langholff, Yanli Wang, Jie Shao, Yevgeniy Krol, Alice B. Gottlieb   +12 more
wiley   +1 more source